Media News
Current News
- Binding Site Announces the launch of a new clinical trial for patients suffering from myeloma kidney09 June 2008
- New partnership expands infectious disease product range21 April 2008
- Binding Site Board Changes18 March 2008
- Myeloma Today interview with Dr Sundar Jagannath10 March 2008
- Financial results for the year ended 30th September 200718 February 2008
- Binding Site article in FT Money30 January 2008
- Innovative Cancer Marker wins Queen’s Award05 November 2007
- Serum free light chain assay recommended in initial investigation of myeloma19 October 2007
09 June 2008
Binding Site Announces the launch of a new clinical trial for patients suffering from myeloma kidney
The Binding Site Limited ("Binding Site" or the "Company"), a privately owned specialist U.K. diagnostics company, today announces the recruitment of the first patient suffering from myeloma kidney onto the EuLITE trial.
EuLITE is a randomised control trial being carried out across a number of British and German Acute nephrology units. It combines use of Freelite™ to monitor levels of nephrotoxic free light chains in serum, light chain removal using a high cut off haemodialysis filter (HCO1100, Gambro) and tumour kill with Velcade-based chemotherapy, with the aim of restoring renal function in patients with myeloma kidney.
EuLITE is based on a pilot study conducted at the Queen Elizabeth Hospital, Birmingham. Renal function was restored in over 70% of myeloma patients treated with high cut off haemodialysis and chemotherapy. This represents a significant improvement over historical controls in which only 11% became dialysis-independent. Restoring renal function in myeloma patients is associated with an increase in life expectancy from 6 months to several years and dramatic gains in quality of life.
Further information on the trial is included in the notes to editors below.
Commenting on today's announcement, Paul Duncan, Chief Executive Officer of Binding Site, said:
"I am delighted to announce the recruitment of the first patient for the new EuLITE trial. The availability of Freelite for measuring serum levels of immunoglobulin free light chains in myeloma patients has allowed the accurate assessment of removal therapies for the first time. It is hoped that combined with high cut-off haemodialysis and efficacious chemotherapy the management of myeloma kidney patients and their future outcome can be significantly improved."
Notes to editors
.jpg)